The minibodies are inert in the body but can be used monitor immune activity, such as the infiltration of CD8 ... drug on the market – PD-L1 inhibitor Imfinzi (durvalumab) which made almost ...

Imfinzi plus BCG therapy significantly improved DFS in high-risk NMIBC patients compared to BCG alone, as shown in the POTOMAC phase 3 trial. The trial was not statistically powered for overall ...

Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs.

Earlier this year, AstraZeneca took Imfinzi to new heights in muscle-invasive bladder cancer (MIBC) with an FDA nod that made it the first immunotherapy cleared to treat patients both before and ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG ...

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with AstraZeneca’s Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy ...

AstraZeneca's human monoclonal antibody Imfinzi (durvalumab), when combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, showed disease-free survival ...

Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial ...

AstraZeneca (AZ) has shared promising results from a late-stage study of its immunotherapy Imfinzi (durvalumab) in non-muscle-invasive bladder cancer (NMIBC). The phase 3 POTOMAC trial has been ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) ...

Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI ® (durvalumab) plus standard-of-care BCG induction and maintenance therapy ...